Theranostics Market Size & Growth Forecast 2027–2036, By Segments (Product, End-use, Application), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Theranostics Market size was around USD 3.05 Billion in 2026 and is slated to grow at 14.14% CAGR from 2027 to 2036, attaining USD 11.45 Billion by 2036. The industry revenue for 2027 is calculated at USD 3.42 Billion.
Get more details on this report
Request Free Sample ReportTheranostics Market Intelligence Snapshot
Regional Market Dynamics
- North America leads through advanced precision medicine capabilities, clinical research infrastructure, biomarker identification, sophisticated diagnostics, and established healthcare institutions supporting personalized treatment adoption.
- Asia Pacific is the fastest-growing region, supported by improving healthcare infrastructure, biotechnology and molecular diagnostics investment, advanced diagnostics access, and growing interest in personalized treatments.
Segment Momentum
- Diagnostic imaging captured 36.5% of the market in 2026 due to its vital role in disease detection, treatment planning, and patient monitoring, supporting more informed decisions for targeted therapies and personalized medicine.
- Radiopharmaceuticals are the fastest-growing segment because they combine diagnostic and therapeutic capabilities, enabling personalized patient management while supporting the growing adoption of targeted treatment strategies and advanced nuclear medicine solutions.
Market Expansion Drivers
- Rising geriatric population increasing demand for precision diagnostic and targeted therapy integration
- Growth in precision medicine accelerating adoption of imaging-linked therapeutic decision systems
- Advancements in molecular imaging and radiopharmaceuticals enabling personalized cancer treatment pathways
Leading Market Participants
- Major players in the theranostics market include Siemens Healthineers AG (Germany), GE HealthCare Technologies Inc. (United States), Koninklijke Philips N.V. (Netherlands), F. Hoffmann-La Roche Ltd (Switzerland), Thermo Fisher Scientific Inc. (United States), Bayer AG (Germany), Canon Medical Systems Corporation (Japan), Curium (France), Lantheus Holdings, Inc. (United States), Cardinal Health, Inc. (United States)
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 3.05 Billion
- 2027 Estimated Market Size: USD 3.42 Billion
- Projected Market Size: USD 11.45 Billion by 2036
- Growth Forecast: 14.14% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Diagnostic Imaging (Product) | Hospitals (End-use) | Prostate Cancer (Application)
- Emerging Opportunity Segment: Radiopharmaceuticals (Product) | Hospitals (End-use) | Neuroendocrine Tumors (Application)
Market Growth Drivers and Industry Trends
Rising geriatric population increasing demand for precision diagnostic and targeted therapy integration
The expanding elderly population will drive the theranostics market growth as age-related diseases, particularly cancer and other chronic conditions, increase the need for integrated diagnostic and therapeutic approaches. Older patients often require personalized treatment strategies that account for disease progression and individual health profiles, making theranostic technologies valuable for optimizing clinical decision-making. By combining precise disease identification with targeted treatment selection, these approaches help clinicians tailor interventions while reducing unnecessary exposure to ineffective therapies.
Growth in precision medicine accelerating adoption of imaging-linked therapeutic decision systems
Rapid advancements in precision medicine are strengthening the theranostics market by increasing the adoption of imaging-guided therapeutic decision systems that enable individualized patient management. Healthcare providers are increasingly utilizing molecular and functional imaging to identify disease characteristics, monitor treatment response, and select therapies that align with specific biological markers. This integration of diagnostics and treatment planning supports more informed clinical decisions while improving the efficiency of personalized care pathways across multiple therapeutic areas.
Advancements in molecular imaging and radiopharmaceuticals enabling personalized cancer treatment pathways
Continuous innovation in molecular imaging technologies and radiopharmaceutical development will boost the theranostics market demand by expanding the ability to diagnose and treat cancer with greater precision. Advanced imaging techniques provide detailed visualization of disease at the molecular level, while targeted radiopharmaceuticals deliver therapeutic agents directly to affected tissues, minimizing damage to surrounding healthy structures. These complementary technologies support individualized oncology treatment planning by enabling accurate disease characterization, therapy selection, and ongoing assessment of therapeutic response.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising geriatric population increasing demand for precision diagnostic and targeted therapy integration | 2.8% | High | North America, Europe | High | Mid Term |
| Growth in precision medicine accelerating adoption of imaging-linked therapeutic decision systems | 3% | High | North America, Asia Pacific | High | Near Term |
| Advancements in molecular imaging and radiopharmaceuticals enabling personalized cancer treatment pathways | 3.1% | High | Europe, North America | High | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
North America dominated the theranostics market in 2026, benefiting from advanced precision medicine capabilities, strong clinical research infrastructure, and increasing adoption of personalized approaches to disease management. The region's sophisticated healthcare ecosystem supports the integration of diagnostic information with targeted therapeutic strategies, particularly in areas where molecular profiling can guide treatment selection and patient monitoring. Growing awareness of precision medicine, improvements in biomarker identification, and expanding use of advanced diagnostic technologies are strengthening demand for theranostic approaches. Furthermore, established healthcare institutions and research capabilities facilitate the development and clinical adoption of therapies linked to patient-specific diagnostic information, supporting the region's leading position.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is projected to be the fastest-growing regional market, driven by improving healthcare infrastructure, expanding access to advanced diagnostics, and rising interest in personalized treatment strategies. Increasing investments in biotechnology, molecular diagnostics, and specialized healthcare services are creating favorable conditions for theranostics adoption. The region is also experiencing growing demand for more targeted and efficient treatment approaches as healthcare systems seek to improve clinical outcomes and optimize the use of therapeutic interventions. Expansion of precision medicine capabilities, greater availability of advanced diagnostic technologies, and increasing awareness among healthcare providers are expected to support broader integration of theranostic solutions across Asia Pacific.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
United States 🇺🇸
Precision Oncology IntegrationThe U.S. continues to prioritize theranostics through expanding clinical adoption, radiopharmaceutical development, and integrated diagnostic-therapy pathways. Healthcare providers in the U.S. are increasing investments in specialized imaging infrastructure and multidisciplinary treatment programs to support personalized cancer care.
Germany 🇩🇪
Clinical Translation FocusGermany emphasizes the clinical translation of theranostics by strengthening collaboration between university hospitals, nuclear medicine specialists, and radiopharmaceutical manufacturers. The country's focus on standardized treatment protocols supports broader adoption across oncology care settings.
Japan 🇯🇵
Radiopharmaceutical InnovationJapan is advancing the theranostics market through continued development of targeted radiopharmaceuticals and expanded use of molecular imaging in oncology. Japanese healthcare institutions are integrating precision treatment approaches while reinforcing manufacturing quality and clinical validation.
South Korea 🇰🇷
Advanced Imaging ExpansionSouth Korea is reinforcing theranostics adoption by expanding advanced diagnostic imaging capabilities alongside targeted radionuclide therapies. Collaboration between research institutes and healthcare providers in South Korea supports the commercialization of innovative precision oncology solutions.
France 🇫🇷
Hospital-Based Nuclear CareFrance supports theranostics through hospital-centered nuclear medicine networks that facilitate coordinated diagnostic and therapeutic services. French healthcare organizations continue to strengthen access to specialized radiopharmaceutical treatments within established oncology care pathways.
Italy 🇮🇹
Specialized Oncology NetworksItaly is expanding theranostics through specialized oncology and nuclear medicine centers that increasingly integrate targeted imaging with therapeutic procedures. Italian healthcare providers are improving coordination across clinical disciplines to enhance personalized treatment delivery.
Segment Leadership and Growth Trends
Theranostics Market Share (%), by Product, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportProduct Segment Analysis: Diagnostic Imaging (Largest Segment) vs Radiopharmaceuticals (Fastest-Growing Segment)
The diagnostic imaging segment dominated the theranostics market, accounting for a 36.5% share in 2026, supported by its essential role in disease detection, treatment planning, and patient monitoring. Imaging technologies enable precise visualization of disease progression and help healthcare professionals make informed decisions regarding targeted therapies. The growing adoption of personalized medicine approaches and increasing demand for accurate diagnostic solutions have strengthened the position of diagnostic imaging as a key component of theranostics applications.
Radiopharmaceuticals are expected to be the fastest-growing segment, driven by their increasing importance in targeted diagnosis and therapy, particularly for complex diseases requiring precision treatment approaches. These products combine diagnostic and therapeutic capabilities, enabling more personalized patient management. Growing interest in advanced nuclear medicine solutions and the shift toward targeted treatment strategies are supporting wider adoption of radiopharmaceuticals within the theranostics landscape.
End-use Segment Analysis: Hospitals (Largest & Fastest-Growing Segment)
The hospitals segment led the theranostics market with a 44.63% share in 2026 and is also expected to remain the fastest-growing segment, owing to the availability of advanced medical infrastructure, specialized healthcare professionals, and comprehensive diagnostic and treatment facilities. Hospitals are increasingly adopting theranostic approaches to provide integrated disease management by combining accurate diagnosis with targeted therapeutic interventions. The expanding focus on personalized healthcare delivery and the increasing use of advanced treatment technologies continue to reinforce the importance of hospitals as the primary end users of theranostics solutions.
Application Segment Analysis: Prostate Cancer (Largest Segment) vs Neuroendocrine Tumors (Fastest-Growing Segment)
The prostate cancer segment held the largest share of the theranostics market, accounting for 27.43% in 2026, due to the growing application of targeted diagnostic and therapeutic approaches for prostate cancer management. Theranostic solutions enable clinicians to identify disease characteristics and deliver more precise treatment strategies, improving patient care outcomes. Increasing emphasis on precision oncology and the need for personalized cancer therapies have supported the strong adoption of theranostic applications in prostate cancer.
Neuroendocrine tumors are emerging as the fastest-growing segment, supported by rising demand for specialized diagnostic methods and targeted therapeutic options for these complex conditions. Theranostic approaches offer significant value in identifying tumor characteristics and guiding individualized treatment decisions. Increasing awareness of advanced oncology solutions and the growing adoption of precision-based treatment methods are contributing to the rapid expansion of this application segment.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Product | Diagnostic Imaging, Radiopharmaceuticals, IVD/Biomarker Screeening, Software and Services | Diagnostic Imaging | Radiopharmaceuticals |
| End-use | Hospitals, Diagnostics Centers, Specialty18 Specialty Clinics, Others | Hospitals | Hospitals |
| Application | Prostate Cancer, Bone Metastasis, Neuroendocrine Tumors, Lymphoma, Cardiovascular Diseases, Others | Prostate Cancer | Neuroendocrine Tumors |
Competitive Landscape and Market Positioning
Prominent players in the theranostics market:
- Siemens Healthineers AG (Germany)
- GE HealthCare Technologies, Inc. (United States)
- Koninklijke Philips N.V. (Netherlands)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Thermo Fisher Scientific, Inc. (United States)
- Bayer AG (Germany)
- Canon Medical Systems Corporation (Japan)
- Curium (France)
- Lantheus Holdings, Inc. (United States)
- Cardinal Health, Inc. (United States)
Advances in precision medicine are reshaping competitive dynamics as market participants increasingly align diagnostic capabilities with targeted therapeutic applications instead of developing these technologies independently. Organizations that can navigate the scientific, manufacturing, and regulatory requirements associated with integrated clinical pathways are strengthening their market position, particularly where personalized treatment approaches demand close coordination between imaging and therapy. Competition is also expanding into specialized production capabilities and supply chain reliability, reflecting the growing importance of consistently delivering complex products that require stringent quality control throughout the care continuum.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Siemens Healthineers AG (Germany) | |||||||
| GE HealthCare Technologies Inc. (United States) | |||||||
| Koninklijke Philips N.V. (Netherlands) | |||||||
| F. Hoffmann-La Roche Ltd (Switzerland) | |||||||
| Thermo Fisher Scientific Inc. (United States) | |||||||
| Bayer AG (Germany) | |||||||
| Canon Medical Systems Corporation (Japan) | |||||||
| Curium (France) | |||||||
| Lantheus Holdings Inc. (United States) | |||||||
| Cardinal Health Inc. (United States) |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Radnostix | Jul-26 | Radnostix completed the asset acquisition of Lucerno Dynamics, absorbing the LARA System technology platform, ELLEXA Explorer software, and related intellectual property to strengthen its proprietary theranostics technology portfolio and competitive market positioning. |
| Siemens Healthineers | Jun-26 | Siemens Healthineers established a new radiopharmacy facility in Dunstable, UK, directly expanding domestic PET radiopharmaceutical production capacity and optimizing supply chain resilience for theranostics and molecular imaging applications. |
| EDAP TMS S.A. | May-26 | EDAP TMS S.A. entered into a strategic collaboration with Telix to integrate robotic high-intensity focused ultrasound with theranostic approaches, establishing an innovative clinical pathway for the precision treatment of prostate cancer. |
| BAMF Health | May-26 | BAMF Health secured nearly $60 million toward a $129.5 million funding round to accelerate the nationwide expansion of its specialized theranostics-focused cancer clinic network across the United States, directly scaling clinical delivery capacity. |
| ICPO | Feb-26 | ICPO signed a strategic partnership with UroTeragLATAM to expand patient access to theranostics for urological cancers across Latin America, leveraging collaborative cross-border initiatives to accelerate broader regional market adoption. |
| BAMF Health | Jan-26 | BAMF Health partnered with Henry Ford Health to establish a comprehensive theranostics center in Detroit, integrating clinical care models to expand regional access to precision medicine, molecular imaging, and radiopharmaceutical therapies. |
| Telix Pharmaceuticals | Dec-25 | Telix Pharmaceuticals entered a strategic clinical collaboration with Varian to develop integrated oncology applications combining theranostic products with external beam radiation therapy, expanding the operational footprint of combination radiopharmaceutical protocols. |
| SpectronRx | May-25 | SpectronRx partnered with Purdue University to establish a dedicated radiopharmaceutical manufacturing training facility, addressing critical value chain requirements by supporting workforce development for the expanding theranostics sector. |
| ROTOP Pharmaka | Jan-25 | ROTOP Pharmaka secured strategic growth financing from GENUI and SHS Capital to expand its radiopharmaceutical manufacturing capabilities, reinforcing its competitive positioning as a specialized commercial CDMO and manufacturing partner within the ecosystem. |
| GE HealthCare | Sep-23 | GE HealthCare formed a strategic collaboration with Mayo Clinic dedicated to joint research and product development in medical imaging and theranostics, leveraging combined clinical expertise and technological capabilities to accelerate pipeline innovation. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Theranostics Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Biomarker Type | Genetic Biomarkers, Protein Biomarkers, Molecular Imaging Biomarkers, Multi-Biomarker Panels |
| Treatment Line | First-Line Therapy, Second-Line Therapy, Third-Line & Later Therapy, Maintenance & Consolidation Therapy |
| Reimbursement Pathway | Public Insurance, Private Insurance, Mixed Public-Private Coverage, Self-Pay & Other Funding |
Theranostics Market — Custom
| Custom Chapter | Custom Details |
|---|---|
| Precision Treatment Pathway Mapping |
|
| Radiopharmaceutical Supply Chain Resilience |
|
| Nuclear Medicine Capacity Readiness |
|
Need a different cut of the data?
Request Custom ResearchHow big is the theranostics market?
What is the anticipated CAGR of the theranostics industry?
How is precision medicine influencing adoption in the theranostics market?
Why are advances in molecular imaging and radiopharmaceuticals strategically important for the theranostics market?
Why is diagnostic imaging the largest product segment in the theranostics market?
What is driving the rapid growth of radiopharmaceuticals in the theranostics market?
Why does North America dominate the theranostics market?
How is Asia Pacific expanding its theranostics market?
Who are the major participants shaping the theranostics landscape?
Our Clients
"The reports offered a comprehensive view of the Food and Beverage landscape, covering market trends, consumer behavior, and competitive dynamics."
"Our experience in acquiring market research reports has been outstanding — the depth of analysis and actionable insights have proven invaluable."
"Fundamental Business Insights demonstrated a keen understanding of our business needs, delivering reports tailored to our specific objectives."
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source | Why It Matters | Reference |
|---|---|---|
| World Health Organization (WHO) | Global health statistics, disease burden, healthcare policies | www.who.int |
| U.S. Food & Drug Administration (FDA) | Medical devices, pharmaceuticals, diagnostics, approvals | www.fda.gov |
| European Medicines Agency (EMA) | Pharmaceutical approvals and regulatory guidance in Europe | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | Disease surveillance, public health, epidemiology | www.cdc.gov |
| National Institutes of Health (NIH) | Biomedical research, clinical studies, funding | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | Biomedical databases, PubMed, genomics | www.ncbi.nlm.nih.gov |
| PubMed | Peer-reviewed biomedical literature | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | Global clinical trial registry | clinicaltrials.gov |
| International Organization for Standardization (ISO) | Medical device quality and healthcare standards | www.iso.org |
| ASTM International | Medical device testing and material standards | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | Medical devices and diagnostics industry | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | Medical device innovation and regulatory science | mdic.org |
| Biotechnology Innovation Organization (BIO) | Biotechnology industry developments | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | Global pharmaceutical industry | www.ifpma.org |
| U.S. Pharmacopeia (USP) | Drug quality standards and reference materials | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | European pharmaceutical quality standards | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | Veterinary healthcare and animal diseases | www.woah.org |
| American Hospital Association (AHA) | Hospital operations and healthcare delivery | www.aha.org |
| OECD Health | International healthcare expenditure and system statistics | www.oecd.org/health |
| World Bank Data | Healthcare expenditure and demographic indicators | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization